These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7488437)

  • 41. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial.
    Gebbia V; Cannata G; Testa A; Curto G; Valenza R; Cipolla C; Latteri MA; Gebbia N
    Cancer; 1994 Oct; 74(7):1945-52. PubMed ID: 8082100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral ondansetron: a useful addition to the supportive care armamentarium?
    Hesketh PJ
    Am J Clin Oncol; 1994 Apr; 17(2):147-9. PubMed ID: 8141106
    [No Abstract]   [Full Text] [Related]  

  • 43. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
    Depierre A
    Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
    Hamadani M; Awab A; Chaudhary L; Tfayli A
    J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
    [No Abstract]   [Full Text] [Related]  

  • 45. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
    J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
    Kwong WJ; Parasuraman TV
    Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting.
    Lacerda JF; Martins C; Carmo JA; Lourenço MF; Araújo Pereira ME; Rodrigues A; Juncal C; Lacerda JM
    Transplant Proc; 2000 Dec; 32(8):2680-1. PubMed ID: 11134761
    [No Abstract]   [Full Text] [Related]  

  • 49. Advances in the control of chemotherapy-induced emesis.
    Perez EA; Gandara DR
    Ann Oncol; 1992 Aug; 3 Suppl 3():47-50. PubMed ID: 1390317
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].
    Galy G; Labidi SI; Tissier F; Combes JD; Auger A; Favier B; Latour JF
    Bull Cancer; 2009 Feb; 96(2):141-5. PubMed ID: 19258220
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
    Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
    Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours.
    Leong SS; Teo CP; Tao M; Ang PT
    Singapore Med J; 1998 Sep; 39(9):396-8. PubMed ID: 9885717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
    Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
    Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
    Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R
    Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
    J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cannabinoids and emesis: new evidences, new questions].
    Duran M; Abanades S; Farré M; Capellà D
    Med Clin (Barc); 2006 Jul; 127(6):237-8; author reply 238. PubMed ID: 16938247
    [No Abstract]   [Full Text] [Related]  

  • 58. Ondansetron suppository: a randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. The Ondansetron Suppository emesis study group.
    Davidson NG; Paska W; Van Belle S; Goedhals L; McQuade B; McRae J
    Oncology; 1997; 54(5):380-6. PubMed ID: 9260599
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ondansetron as an antiemetic.
    Reed MD
    Br J Clin Pharmacol; 1992 Aug; 34(2):144. PubMed ID: 1419476
    [No Abstract]   [Full Text] [Related]  

  • 60. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.